MEIRAGTX HOLDINGS PLC

MGTXNASDAQ

🏆 #1823 by market capEarnings Aug 13US Equity

$13.05▲ $0.03 (+0.23%)

🌙 After hours$13.05▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 0.2%

7d—

14d—

30d—

1y—

🏦Market Cap

$1.21B

Small Cap

📈Revenue Growth (YoY)

+144.6%

High Growth

📊Gross Margin

91.6%

High

💵FCF Margin

-2.9%

Thin

⚖️P/S Ratio

15.2x

Expensive

Otter Score

Weak

No chart data available for MGTX.

Trading Snapshot

Day Range: $12.98 – $13.12
52-Week Range: $6.62 – $15.35
Volume: $1.80B
Avg Volume: $1.97B
Shares Outstanding: 92.6M
Next Earnings: Oct 8, 2026

Fundamentals Snapshot

Annual Revenue: $81M
Last Q Revenue: $293,000
P/E Ratio: -8.8
P/S Ratio: 15.2x
EPS (TTM): $-1.48
Dividend Yield: 0.00%

Why Investors Own MGTX

✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
✓Healthy economics — 34% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$81M▲ +0.5% YoY

Gross Margin (TTM)

34.4%▲ +1.7% YoY

Operating Income (TTM)

$17M▲ +0.5% YoY

Free Cash Flow (TTM)

$5M▲ +0.5% YoY

About MEIRAGTX HOLDINGS PLC

MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.

🦦